A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)
Trial Parameters
Brief Summary
To learn if adding 1 year of therapy with pembrolizumab can help to continue to control RCC after radiation therapy.
Eligibility Criteria
Inclusion Criteria: In order to be eligible for trial participation, patients must have: 1. The participant provides written informed consent for the trial. 2. Pathologically confirmed diagnosis of RCC with a clear cell component. 3. Be willing and able to undergo biopsy of a lesion planned for definitive RT. If a lesion amenable to SBRT was biopsied prior to enrollment, this material can be used in lieu of a planned biopsy if the tissue is available for review at MD Anderson. 1. Patients may be allowed on this trial without a biopsy if they are deemed medically unfit for biopsy or if the biopsy poses undue risk in the opinion of the treating physician(s). 4. Be ≥18 years of age on the day of signing informed consent. 5. ECOG performance status 0-1. NOTE: If subject is unable to walk due to paralysis, but is mobile in a wheelchair, subject is ambulatory for the purpose of assessing their performance status. 1. Have measurable disease based on RECIST 1.1. Lesions situated in a previousl